respiratory | mecfa

MECFA Blog

Protein Called TAS2R38 Linked to Respiratory Tract Complications in CF

Problems with a protein called TAS2R38 are linked to a greater risk of severe sinonasal disease and Pseudomonas aeruginosa lung...

UHG Adult Cystic Fibrosis Team to use online videos for outpatient consultations

Galway Bay fm newsroom: The Adult Cystic Fibrosis Team at UHG will use online video conferencing instead of face-to-face outpatient...

CF patients experience improved lung health with lumacaftor-ivacaftor but with caveats

In adolescent and adult patients with cystic fibrosis taking lumacaftor-ivacaftor (ORKAMBI), the combination drug appears to improve lung...

Viral Respiratory Tract Infections in Young CF Children Usually Mild, Study Found

Viral respiratory tract infections in young children with cystic fibrosis tend to be mild and not require hospitalization, a study found....

Hexoskin Smart Shirt Can Accurately Assess Respiratory Function, May Be Tool in CF, Study Shows

Using a simple shirt — a smart one — is closer to becoming a common method to measure lung function in patients with respiratory...

Personalized Nutrition Programs May Help Improve Outcomes for CF Patients, Survey Suggests

New personalized strategies that can address the nutritional needs of cystic fibrosis patients may provide the best care and improve...

Cystic Fibrosis: Antioxidant-Enriched MVI May Decrease Respiratory Illnesses

MedicalResearch.com Interview with: Scott D Sagel MD PhD Professor of Pediatrics University of Colorado School of Medicine Aurora,...

Study finds antioxidant-enriched vitamin reduces respiratory illnesses in patients with CF

Children's Hospital Colorado and the University of Colorado School of Medicine lead a multicenter clinical trial that identifies benefits...

Improving Antibiotic Strategies To Combat Respiratory Infections In Cystic Fibrosis Patients

Cystic fibrosis (CF) is an inherited, progressive disease caused by mutations in the cystic fibrosis transmembrane regulator (CFTR)...

Disease Duration, Flare-ups Affect Mental Health of Non-CF Bronchiectasis Patients, Study Finds

VERTEX’S CF BLOCKBUSTER TRIKAFTA EFFECTIVE IN KIDS 6 TO 11 YEARS OF AGE

A case for improved carrier screening

Vertex to Seek Expanded FDA Approval for Trikafta After Positive Child Safety Data

Vertex’s Kaftrio approved for use in Europe and made accessible on the NHS

Age May Affect Outcomes in Lung Transplant Recipients With Cystic Fibrosis

CFF Funding Will Further ContraFect’s Research Into Alternative for Antibiotics

The search for molecular glue in targeted disease control

Vest Therapy Lowers Risk of Hospitalization in Non-CF Bronchiectasis, Study Says

Harvard is working with Boston hospitals to test existing cystic fibrosis drug to help coronavirus p